Hereditary Angioedema Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Key Companies - Takeda, Shire, CSL Behring, Pharming Group, BioCryst Pharmaceuticals, KalVista, Ionis Pharmaceuticals

As per DelveInsight, the Hereditary Angioedema Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Hereditary Angioedema and the launch of new therapies in the market.

DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hereditary Angioedema Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Hereditary Angioedema therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Hereditary Angioedema treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Hereditary Angioedema: An Overview
Hereditary Angioedema (HAE) is a rare genetic disorder caused by a deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or mucosal edema, most commonly affecting the skin, intestines, upper respiratory tract, and oropharynx

HAE is a heterogeneous disease with complex pathophysiology that involves several pathways resulting in the increased production of bradykinin with mutations of multiple molecules in genetic etiology. These could include the Kallikrein gene mutations; Bradykinin gene or its receptor mutations; Kininase 1 gene mutations and loss of function and mutations in gene encoding aminopeptidase and ACE enzymes.

It is classified into three types based on genetic defects such as type I HAE with low levels of C1-INH in the body, type II with poorly functioning C1-INH, or the recently identified types of HAE with normal functioning C1-INH (formerly known as type III HAE). Identification of the novel polymorphisms in several genes leading to modification in the clinical phenotype of HAE is a relatively recent phenomenon.

Treatment of HAE has evolved with advancement in understanding the pathogenesis of this disease. It is directed towards either replacing the defective protein or blocking various molecules involved in the production of bradykinin or the bradykinin receptor. The current standard of care for HAE attacks are C1 inhibitors, ecallantide, or icatibant. If these drugs are not available then attacks are being treated with solvent detergent-treated plasma (SDP) and frozen plasma.

Hereditary Angioedema Market Key Facts
• In 2021, EU4 and the UK countries captured an estimated USD 347 million, which is expected to rise by 2032.
• The expected launch of potential therapy may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of Hereditary Angioedema.
• Upcoming therapy such as Garadacimab, Donidalorsen has the potential to create a significant positive shift in the Hereditary Angioedema (HAE) market size.
• The total diagnosed prevalent cases of HAE in the 7MM+China was found to be 14,375 approximately in 2021, which might increase by the end of 2032. These cases are expected to increase at a considerable CAGR during the study period (2019-2032).
• Among the European countries, the UK had the highest diagnosed prevalent population of HAE, with approximately 1,348 cases, followed by Germany, which had 1,266 diagnosed prevalent population in 2021. On the other hand, Spain and Italy had the lowest and equal number of diagnosed prevalent populations, with approximately 942 cases in 2021.
• Japan accounted for approximately 462 diagnosed prevalent cases of HAE in the year 2021 which is expected to decrease during the forecasted period (2022-2032).

Discover How Hereditary Angioedema Market Will Grow by 2032:
https://www.delveinsight.com/report-store/hereditary-angioedema-hae-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Hereditary Angioedema Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Hereditary Angioedema therapies in the market. It also provides a detailed assessment of the Hereditary Angioedema market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Hereditary Angioedema drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Hereditary Angioedema Epidemiology
The epidemiology section covers detailed insights into the historical, and current Hereditary Angioedema patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Hereditary Angioedema Epidemiology Segmented as -
• Total Diagnosed Prevalent Cases of Hereditary Angioedema[2019-2032]
• Site-specific cases of Hereditary Angioedema [2019-2032]
• Type-specific cases of Hereditary Angioedema [2019-2032]
• Age-specific cases of Hereditary Angioedema [2019-2032]
• Gender-specific cases of Hereditary Angioedema [2019-2032]

Get Key Insights Into the Evolving Hereditary Angioedema Epidemiology Trends @
https://www.delveinsight.com/report-store/hereditary-angioedema-hae-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Hereditary Angioedema Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Angioedema market or expected to be launched during the study period. The analysis covers the market share by Hereditary Angioedema drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Hereditary Angioedema Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/hereditary-angioedema-hae-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Hereditary Angioedema Therapeutics Assessment
Several major pharma and biotech companies are developing therapies for Hereditary angioedema. Currently, KalVista Pharmaceuticals is leading the therapeutics market with its Hereditary angioedema drug candidates in the most advanced stage of clinical development.

Leading Companies in the Hereditary Angioedema Therapeutics Market Include
• BioCryst Pharmaceuticals
• KalVista Pharmaceuticals
• Pharvaris
• BioMarin Pharmaceutical
• Ionis Pharmaceuticals, Inc.
• Intellia Therapeutics
And Many Others

Emerging and Marketed Hereditary Angioedema Therapies Covered in the Report Include
• Takhzyro: Takeda
• Firazyr: Shire/Takeda
• Cinryze: Shire/Takeda
• Kalbitor: Shire/Takeda
• Haegarda: CSL Behring
• Berinert: CSL Behring
• Ruconest: Pharming Group
• BCX7353: BioCryst Pharmaceuticals
• IONIS-PKK-LRx: Ionis Pharmaceuticals
• KVD900: KalVista Pharmaceuticals
• CSL312: CSL Behring
And Many More

Learn More About the Emerging Therapies & Key Companies in the Hereditary Angioedema Therapeutics Market:
https://www.delveinsight.com/sample-request/hereditary-angioedema-hae-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Hereditary Angioedema Competitive Intelligence Analysis
4. Hereditary Angioedema Market Overview at a Glance
5. Hereditary Angioedema Background and Overview
6. Hereditary Angioedema Patient Journey
7. Hereditary Angioedema Epidemiology and Patient Population
8. Hereditary Angioedema Treatment Algorithm, Current Treatment, and Medical Practices
9. Hereditary Angioedema Unmet Needs
10. Key Endpoints of Hereditary Angioedema Treatment
11. Hereditary Angioedema Marketed Products
12. Hereditary Angioedema Emerging Therapies
13. Hereditary Angioedema Seven Major Market Analysis
14. Attribute Analysis
15. Hereditary Angioedema Market Outlook (7 major markets)
16. Hereditary Angioedema Access and Reimbursement Overview
17. KOL Views on the Hereditary Angioedema Market.
18. Hereditary Angioedema Market Drivers
19. Hereditary Angioedema Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/hereditary-angioedema-hae-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Dementia with Diabetes Market
https://www.delveinsight.com/report-store/dementia-with-diabetes-market-forecast

Indolent Lymphoma Market
https://www.delveinsight.com/report-store/indolent-lymphoma-market

Liver Angiosarcoma Market
https://www.delveinsight.com/report-store/liver-angiosarcoma-market

Venous Stenosis Market
https://www.delveinsight.com/report-store/venous-stenosis-market

Bronchial Hyperreactivity Market
https://www.delveinsight.com/report-store/bronchial-hyperreactivity-market

Pegfilgrastim Biosimilar
https://www.delveinsight.com/report-store/pegfilgrastim-biosimilar-insight

Cytokine Release Syndrome Market
https://www.delveinsight.com/report-store/cytokine-release-syndrome-market

Primary Progressive Multiple Sclerosis (PPMS) Market
https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-market

Singapore Healthcare Outlook
https://www.delveinsight.com/report-store/singapore-healthcare-outlook-report

Hematuria Market
https://www.delveinsight.com/report-store/hematuria-market

Varicose Ulcer Market
https://www.delveinsight.com/report-store/varicose-ulcer-market

Anaplastic Astrocytoma Market
https://www.delveinsight.com/report-store/anaplastic-astrocytoma-market

Lymphoedema Market
https://www.delveinsight.com/report-store/lymphoedema-market

Morquio Syndrome Market
https://www.delveinsight.com/report-store/morquio-syndrome-market

Nasopharyngeal Carcinoma Market
https://www.delveinsight.com/report-store/nasopharyngeal-carcinoma-market

CART-related Neurotoxicity (NT) Market
https://www.delveinsight.com/report-store/cart-related-neurotoxicity-nt-market

Total Knee Arthroplasty Market
https://www.delveinsight.com/report-store/total-knee-arthroplasty-market

Cushing's Syndrome Market
https://www.delveinsight.com/report-store/cushings-syndrome-market

Tumor Ablation Market
https://www.delveinsight.com/report-store/tumor-ablation-market

Diabetes Market
https://www.delveinsight.com/report-store/diabetes-market

Autism Spectrum Disorder Market
https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market
https://www.delveinsight.com/report-store/blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-market

Urinary Incontinence Market
https://www.delveinsight.com/report-store/urinary-incontinence-market

Seborrhoeic Dermatitis Market Substance (Drug) Abuse Market
https://www.delveinsight.com/report-store/substance-drug-abuse-market

Artificial Cornea and Corneal Implant Market
https://www.delveinsight.com/report-store/artificial-cornea-and-corneal-implant-market

Prosthetic Heart Valve Market
https://www.delveinsight.com/report-store/prosthetic-heart-valve-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.